NFKB1 and cancer: CECR2 was recently recognized as a ‘top epigenetic regulator’ that upregulates NF-κB inflammatory and pro-metastatic genes, emphasizing the therapeutic potential of targeting this bromodomain-containing protein in cancer treatment.